Viewing Study NCT01291420



Ignite Creation Date: 2024-05-05 @ 11:18 PM
Last Modification Date: 2024-10-26 @ 10:31 AM
Study NCT ID: NCT01291420
Status: COMPLETED
Last Update Posted: 2023-05-12
First Post: 2011-02-07

Brief Title: Dendritic Cell Vaccination for Patients With Solid Tumors
Sponsor: University Hospital Antwerp
Organization: University Hospital Antwerp

Study Overview

Official Title: Therapeutic Efficacy of Wilms Tumor Gene WT1 mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors a Phase IFeasibility Study
Status: COMPLETED
Status Verified Date: 2023-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells DCs - engineered to express the WT1 protein - in patients with limited spread metastatic solid tumors ie breast cancers glioblastoma grade IV sarcomas malignant mesothelioma and colorectal tumors Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8 T cell responses
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None